Investigating the availability, affordability, and market dynamics of innovative oncology drugs in Morocco: an original report.

IF 4.5 2区 医学 Q1 PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH
Nada Benhima, Leila Afani, Mohammed El Fadli, Ismail Essâdi, Rhizlane Belbaraka
{"title":"Investigating the availability, affordability, and market dynamics of innovative oncology drugs in Morocco: an original report.","authors":"Nada Benhima, Leila Afani, Mohammed El Fadli, Ismail Essâdi, Rhizlane Belbaraka","doi":"10.1186/s12939-024-02262-9","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The cost of cancer drugs presents a significant challenge to accessibility of treatment worldwide. Projections indicate that by 2040, two-thirds of cancer cases will occur in low- and middle- income countries. Paradoxically, despite this impending burden, LMICs command less than 5% share of global resources for treating cancer. Morocco, like many LMICs, faces significant obstacles in providing innovative cancer treatments to its population.</p><p><strong>Aim: </strong>Firstly, we aimed to conduct an original research investigating the availability and affordability of innovative cancer drugs in Morocco. Secondly, we sought to review the broader market dynamics, pricing, and reimbursement policies in the country.</p><p><strong>Methods: </strong>For the first objective, we identified a preliminary list of medicines approved for oncological indications in the Moroccan market based on resources from ANAM (National Agency for Health Insurance), pharmacy regulators, and online resources that compile information on approved medicines. For the second objective, we exhaustively reviewed the regulatory documents, legal texts and grey literature reports. All the informations were examined by pharma delegates and local experts.</p><p><strong>Results: </strong>As of January 2024, Morocco has 39 innovative anticancer medicines with market authorization. 30% of these drugs were approved after 2020. The majority of approved drugs were for breast, lung, colorectal, and prostate cancer. The period between FDA approval and entry into the Moroccan market ranges from 2 to 7 years, with a median of 3 years for breast cancer drugs and 7 years for more expensive drugs like Olaparib and Osimertinib. 22 out of the 39 drugs are not reimbursed, with an average reimbursement time of 4 years. Compared to prices in France, the most notable pricing disparities concern immunotherapy agents, priced 600 to 900 euros lower in France, while drugs like Pazopanib and Erlotinib cost 50% less in Morocco.</p><p><strong>Conclusion: </strong>Our study reveals significant disparities in the availability and affordability of innovative cancer drugs in Morocco. Regulatory hurdles, importation challenges, and pricing strategies contribute to this inequitable landscape. Addressing systemic barriers, fostering collaborations between stakeholders, and adopting a value-based pricing approach are imperative steps toward ensuring equitable access to high-quality interventions for patients, regardless of their geographical location.</p>","PeriodicalId":13745,"journal":{"name":"International Journal for Equity in Health","volume":null,"pages":null},"PeriodicalIF":4.5000,"publicationDate":"2024-10-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11492621/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal for Equity in Health","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12939-024-02262-9","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The cost of cancer drugs presents a significant challenge to accessibility of treatment worldwide. Projections indicate that by 2040, two-thirds of cancer cases will occur in low- and middle- income countries. Paradoxically, despite this impending burden, LMICs command less than 5% share of global resources for treating cancer. Morocco, like many LMICs, faces significant obstacles in providing innovative cancer treatments to its population.

Aim: Firstly, we aimed to conduct an original research investigating the availability and affordability of innovative cancer drugs in Morocco. Secondly, we sought to review the broader market dynamics, pricing, and reimbursement policies in the country.

Methods: For the first objective, we identified a preliminary list of medicines approved for oncological indications in the Moroccan market based on resources from ANAM (National Agency for Health Insurance), pharmacy regulators, and online resources that compile information on approved medicines. For the second objective, we exhaustively reviewed the regulatory documents, legal texts and grey literature reports. All the informations were examined by pharma delegates and local experts.

Results: As of January 2024, Morocco has 39 innovative anticancer medicines with market authorization. 30% of these drugs were approved after 2020. The majority of approved drugs were for breast, lung, colorectal, and prostate cancer. The period between FDA approval and entry into the Moroccan market ranges from 2 to 7 years, with a median of 3 years for breast cancer drugs and 7 years for more expensive drugs like Olaparib and Osimertinib. 22 out of the 39 drugs are not reimbursed, with an average reimbursement time of 4 years. Compared to prices in France, the most notable pricing disparities concern immunotherapy agents, priced 600 to 900 euros lower in France, while drugs like Pazopanib and Erlotinib cost 50% less in Morocco.

Conclusion: Our study reveals significant disparities in the availability and affordability of innovative cancer drugs in Morocco. Regulatory hurdles, importation challenges, and pricing strategies contribute to this inequitable landscape. Addressing systemic barriers, fostering collaborations between stakeholders, and adopting a value-based pricing approach are imperative steps toward ensuring equitable access to high-quality interventions for patients, regardless of their geographical location.

调查摩洛哥肿瘤创新药物的可用性、可负担性和市场动态:原创报告。
背景:癌症药物的成本对全球治疗的可及性构成了重大挑战。预测显示,到 2040 年,三分之二的癌症病例将发生在中低收入国家。令人不解的是,尽管癌症负担迫在眉睫,中低收入国家在全球癌症治疗资源中所占的份额却不到 5%。目标:首先,我们旨在开展一项原创性研究,调查创新抗癌药物在摩洛哥的可用性和可负担性。其次,我们试图审查该国更广泛的市场动态、定价和报销政策:在第一个目标中,我们根据国家医疗保险局(ANAM)、药房监管机构和汇编已批准药品信息的在线资源,初步确定了摩洛哥市场上已批准的肿瘤适应症药品清单。为了实现第二个目标,我们详尽查阅了监管文件、法律文本和灰色文献报告。所有信息均由医药代表和当地专家进行了审查:截至 2024 年 1 月,摩洛哥共有 39 种创新抗癌药物获得了市场授权。其中 30% 的药物是在 2020 年之后获批的。大部分获批药物用于治疗乳腺癌、肺癌、结直肠癌和前列腺癌。从 FDA 批准到进入摩洛哥市场的时间从 2 年到 7 年不等,乳腺癌药物的中位数为 3 年,奥拉帕利(Olaparib)和奥西莫替尼(Osimertinib)等较昂贵药物的中位数为 7 年。39 种药物中有 22 种没有报销,平均报销时间为 4 年。与法国的价格相比,免疫疗法药物的价格差距最明显,法国的免疫疗法药物价格要低600至900欧元,而帕唑帕尼和厄洛替尼等药物在摩洛哥的价格要低50%:我们的研究揭示了摩洛哥在创新抗癌药物的可获得性和可负担性方面的巨大差异。监管障碍、进口挑战和定价策略造成了这种不公平的局面。解决系统性障碍、促进利益相关者之间的合作以及采用基于价值的定价方法是确保患者(无论其地理位置如何)公平获得高质量干预措施的必要步骤。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
7.80
自引率
4.20%
发文量
162
审稿时长
28 weeks
期刊介绍: International Journal for Equity in Health is an Open Access, peer-reviewed, online journal presenting evidence relevant to the search for, and attainment of, equity in health across and within countries. International Journal for Equity in Health aims to improve the understanding of issues that influence the health of populations. This includes the discussion of political, policy-related, economic, social and health services-related influences, particularly with regard to systematic differences in distributions of one or more aspects of health in population groups defined demographically, geographically, or socially.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信